Market Overview

According to fortune business insights, the global drug eluting stent market size was valued at USD 6.94 billion in 2025. The market is projected to grow from USD 7.59 billion in 2026 to USD 15.52 billion by 2034, exhibiting a CAGR of 9.35% during the forecast period. North America dominated the drug eluting stent market with a market share of 30.82% in 2025.

The analysis shows that the introduction of technologically advanced stents by key market players is anticipated to limit the risk of early and late thrombosis. For example, in February 2019, Biotronik received FDA approval for Orsiro, the first ultrathin, bioresorbable polymer-coated Drug Eluting Stent (DES). This trend indicates strong demand and continuous innovation in the drug eluting stent market worldwide.

Major Players Profiled in the Market Report:

• Boston Scientific Corporation
• Abbott
• Medtronic
• Biotronik
• Terumo Corporation
• MicroPort Scientific Corporation
• Sahajanand Medical Technologies
• Others

Segments

Rising Incidence of Coronary Artery Disease to Propel Coronary Stenting Segment Growth

Based on indication, the market is segmented into coronary stenting and peripheral stenting. The coronary stenting segment holds the largest market share and dominates the market owing to the growing prevalence of coronary artery diseases and a strong preference for Drug Eluting Stents by healthcare providers globally.

High Clinical Effectiveness to Drive Sirolimus Segment Expansion

By drug, the market is categorized into Sirolimus, Paclitaxel, Zotarolimus, Everolimus, & Others. The sirolimus segment is leading the market as there is high preference among end-users for its distinct qualities, which include limited or reduced late lumen loss and angiographic restenosis compared to other options.

Flexibility and Biocompatibility to Dominate Cobalt-Chromium Segment

Based on scaffold, the market is segmented into cobalt-chromium, platinum-chromium, nitinol, and others. The cobalt-chromium segment holds the largest market share owing to the increased use of these stents, which offer flexibility, a long shelf-life, and better biocompatibility, driving high demand.

Higher Adoption in Hospitals to Dominate the Market